Palatine-based Acura Pharmaceuticals Inc., whose technology helps deter drug abuse, sued Ranbaxy Laboratories Ltd., India's largest drugmaker, over its plan to market a generic version of the painkiller Oxecta.
Acura claimed New Delhi-based Ranbaxy wrongly plans to market a copy of the short-acting oxycodone pill before Acura's patent expires in 2025, according to papers filed April 29 in federal court in Delaware.
Contact information ( * required )
"Acura will be substantially and irreparably harmed by Ranbaxy's infringing activities" unless stopped by a judge, according to the complaint.
Ranbaxy reported about $2.2 billion in sales for fiscal 2012. Acura listed about $20 million in fiscal 2011 sales and a net loss last year, according to data compiled by Bloomberg.
Charles M. Caprariello, a U.S. spokesman for Ranbaxy, didn't immediately return a call seeking comment on the lawsuit.
In dispute is patent 7,510,726, issued in March 2009.
The case is Acura v. Ranbaxy, 13-cv-00750, U.S. District Court, District of Delaware (Wilmington).